Publication:
Implementation of proteomic biomarkers: Making it work

Issued Date

2012-09-01

Resource Type

Article

ISSN

13652362
00142972

DOI

10.1111/j.1365-2362.2012.02674.x

Other identifier(s)

2-s2.0-84865194855

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

European Journal of Clinical Investigation. Vol.42, No.9 (2012), 1027-1036

Suggested Citation

Harald Mischak, John P.A. Ioannidis, Angel Argiles, Teresa K. Attwood, Erik Bongcam-Rudloff, Mark Broenstrup, Aristidis Charonis, George P. Chrousos, Christian Delles, Anna Dominiczak, Tomasz Dylag, Jochen Ehrich, Jesus Egido, Peter Findeisen, Joachim Jankowski, Robert W. Johnson, Bruce A. Julien, Tim Lankisch, Hing Y. Leung, David Maahs, Fulvio Magni, Michael P. Manns, Efthymios Manolis, Gert Mayer, Gerjan Navis, Jan Novak, Alberto Ortiz, Frederik Persson, Karlheinz Peter, Hans H. Riese, Peter Rossing, Naveed Sattar, Goce Spasovski, Visith Thongboonkerd, Raymond Vanholder, Joost P. Schanstra, Antonia Vlahou Implementation of proteomic biomarkers: Making it work. European Journal of Clinical Investigation. Vol.42, No.9 (2012), 1027-1036. doi:10.1111/j.1365-2362.2012.02674.x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/13629

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Implementation of proteomic biomarkers: Making it work

Author(s)

Harald Mischak
 John P.A. Ioannidis
 Angel Argiles
 Teresa K. Attwood
 Erik Bongcam-Rudloff
 Mark Broenstrup
 Aristidis Charonis
 George P. Chrousos
 Christian Delles
 Anna Dominiczak
 Tomasz Dylag
 Jochen Ehrich
 Jesus Egido
 Peter Findeisen
 Joachim Jankowski
 Robert W. Johnson
 Bruce A. Julien
 Tim Lankisch
 Hing Y. Leung
 David Maahs
 Fulvio Magni
 Michael P. Manns
 Efthymios Manolis
 Gert Mayer
 Gerjan Navis
 Jan Novak
 Alberto Ortiz
 Frederik Persson
 Karlheinz Peter
 Hans H. Riese
 Peter Rossing
 Naveed Sattar
 Goce Spasovski
 Visith Thongboonkerd
 Raymond Vanholder
 Joost P. Schanstra
 Antonia Vlahou

Other Contributor(s)

University of Glasgow
 Mosaiques Diagnostics
 University of Ioannina, School of Medicine
 Stanford University School of Medicine
 Stanford University
 RD Néphrologie
 University of Manchester
 Uppsala Universitet
 Sveriges lantbruksuniversitet
 Sanofi-Aventis Deutschland GmbH
 Academy of Athens
 University of Athens Medical School
 European Commission
 Medizinische Hochschule Hannover (MHH)
 Universidad Autonoma de Madrid
 Universitatsklinikum Mannheim
 Charité – Universitätsmedizin Berlin
 Abbott Laboratories
 University of Alabama at Birmingham
 Beatson Institute for Cancer Research
 University of Colorado Health Sciences Center
 Universita degli Studi di Milano - Bicocca
 European Medicines Agency
 Medizinische Universitat Innsbruck
 University of Groningen, University Medical Center Groningen
 Steno Diabetes Center
 Baker Heart and Diabetes Institute
 Instituto de Salud Carlos III
 SS Cyril and Methodius University Faculty of Medicine
 Mahidol University
 University Hospital of Ghent
 Universite Paul Sabatier Toulouse III

Abstract

While large numbers of proteomic biomarkers have been described, they are generally not implemented in medical practice. We have investigated the reasons for this shortcoming, focusing on hurdles downstream of biomarker verification, and describe major obstacles and possible solutions to ease valid biomarker implementation. Some of the problems lie in suboptimal biomarker discovery and validation, especially lack of validated platforms with well-described performance characteristics to support biomarker qualification. These issues have been acknowledged and are being addressed, raising the hope that valid biomarkers may start accumulating in the foreseeable future. However, successful biomarker discovery and qualification alone does not suffice for successful implementation. Additional challenges include, among others, limited access to appropriate specimens and insufficient funding, the need to validate new biomarker utility in interventional trials, and large communication gaps between the parties involved in implementation. To address this problem, we propose an implementation roadmap. The implementation effort needs to involve a wide variety of stakeholders (clinicians, statisticians, health economists, and representatives of patient groups, health insurance, pharmaceutical companies, biobanks, and regulatory agencies). Knowledgeable panels with adequate representation of all these stakeholders may facilitate biomarker evaluation and guide implementation for the specific context of use. This approach may avoid unwarranted delays or failure to implement potentially useful biomarkers, and may expedite meaningful contributions of the biomarker community to healthcare. © 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation.

Keyword(s)

Biochemistry, Genetics and Molecular Biology

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/13629

Collections

Scopus 2011-2015